Achieve Life Sciences (ACHV) to Release Earnings on Tuesday

Achieve Life Sciences (NASDAQ:ACHV) will likely be announcing its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect Achieve Life Sciences to post earnings of ($0.27) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 20, 2026 at 9:30 AM ET.

Achieve Life Sciences Trading Down 3.0%

NASDAQ ACHV opened at $4.27 on Monday. Achieve Life Sciences has a 1 year low of $1.84 and a 1 year high of $6.03. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.14 and a quick ratio of 5.14. The company has a market capitalization of $227.29 million, a PE ratio of -3.09 and a beta of 1.81. The company has a fifty day moving average of $4.75 and a 200 day moving average of $4.22.

Hedge Funds Weigh In On Achieve Life Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of ACHV. KVP Capital Advisors LP acquired a new stake in Achieve Life Sciences in the 4th quarter valued at about $2,298,000. Millennium Management LLC boosted its holdings in shares of Achieve Life Sciences by 472.3% during the 4th quarter. Millennium Management LLC now owns 1,359,116 shares of the biopharmaceutical company’s stock worth $6,755,000 after purchasing an additional 1,121,614 shares during the last quarter. Jump Financial LLC acquired a new position in shares of Achieve Life Sciences during the 4th quarter worth approximately $104,000. Osaic Holdings Inc. grew its position in shares of Achieve Life Sciences by 89.9% in the fourth quarter. Osaic Holdings Inc. now owns 53,983 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 25,550 shares in the last quarter. Finally, Graham Capital Management L.P. purchased a new stake in shares of Achieve Life Sciences in the fourth quarter valued at approximately $212,000. 33.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Citigroup assumed coverage on Achieve Life Sciences in a report on Tuesday, November 25th. They issued an “outperform” rating for the company. Citizens Jmp assumed coverage on Achieve Life Sciences in a report on Tuesday, November 25th. They set a “market outperform” rating and a $19.00 target price on the stock. Raymond James Financial reiterated a “strong-buy” rating on shares of Achieve Life Sciences in a research report on Monday, November 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Achieve Life Sciences in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Achieve Life Sciences currently has an average rating of “Moderate Buy” and an average price target of $15.50.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.